JAK inhibition using tofacitinib for inflammatory bowel disease treatment

A hub for multiple inflammatory cytokines

Silvio Danese, Matthew Grisham, Jennifer Hodge, Jean Baptiste Telliez

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The inflammatory diseases ulcerative colitis and Crohn’s disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.

Original languageEnglish
Pages (from-to)G155-G162
JournalAmerican Journal of Physiology - Gastrointestinal and Liver Physiology
Volume310
Issue number3
DOIs
Publication statusPublished - 2016

Fingerprint

Janus Kinases
Inflammatory Bowel Diseases
Cytokines
Inflammation
Therapeutics
Immunologic Factors
Adaptive Immunity
tofacitinib
Ulcerative Colitis
Innate Immunity
Crohn Disease
Gastrointestinal Tract
Immune System
Quality of Life

Keywords

  • Crohn’s disease
  • Inflammation
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology (medical)
  • Physiology
  • Hepatology

Cite this

JAK inhibition using tofacitinib for inflammatory bowel disease treatment : A hub for multiple inflammatory cytokines. / Danese, Silvio; Grisham, Matthew; Hodge, Jennifer; Telliez, Jean Baptiste.

In: American Journal of Physiology - Gastrointestinal and Liver Physiology, Vol. 310, No. 3, 2016, p. G155-G162.

Research output: Contribution to journalArticle

@article{3ce9a41415f447198c829f1349ce779b,
title = "JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines",
abstract = "The inflammatory diseases ulcerative colitis and Crohn’s disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.",
keywords = "Crohn’s disease, Inflammation, Inflammatory bowel disease, Ulcerative colitis",
author = "Silvio Danese and Matthew Grisham and Jennifer Hodge and Telliez, {Jean Baptiste}",
year = "2016",
doi = "10.1152/ajpgi.00311.2015",
language = "English",
volume = "310",
pages = "G155--G162",
journal = "American Journal of Physiology",
issn = "0363-6119",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - JAK inhibition using tofacitinib for inflammatory bowel disease treatment

T2 - A hub for multiple inflammatory cytokines

AU - Danese, Silvio

AU - Grisham, Matthew

AU - Hodge, Jennifer

AU - Telliez, Jean Baptiste

PY - 2016

Y1 - 2016

N2 - The inflammatory diseases ulcerative colitis and Crohn’s disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.

AB - The inflammatory diseases ulcerative colitis and Crohn’s disease constitute the two main forms of inflammatory bowel disease (IBD). They are characterized by chronic, relapsing inflammation of the gastrointestinal tract, significantly impacting on patient quality of life and often requiring prolonged treatment. Existing therapies for IBD are not effective for all patients, and an unmet need exists for additional therapies to induce and maintain remission. Here we describe the mechanism of action of the Janus kinase (JAK) inhibitor, tofacitinib, for the treatment of IBD and the effect of JAK inhibition on the chronic cycle of inflammation that is characteristic of the disease. The pathogenesis of IBD involves a dysfunctional response from the innate and adaptive immune system, resulting in overexpression of multiple inflammatory cytokines, many of which signal through JAKs. Thus JAK inhibition allows multiple cytokine signaling pathways to be targeted and is expected to modulate the innate and adaptive immune response in IBD, thereby interrupting the cycle of inflammation. Tofacitinib is an oral, small molecule JAK inhibitor that is being investigated as a targeted immunomodulator for IBD. Clinical development of tofacitinib and other JAK inhibitors is ongoing, with the aspiration of providing new treatment options for IBD that have the potential to deliver prolonged efficacy and clinically meaningful patient benefits.

KW - Crohn’s disease

KW - Inflammation

KW - Inflammatory bowel disease

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84956881232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956881232&partnerID=8YFLogxK

U2 - 10.1152/ajpgi.00311.2015

DO - 10.1152/ajpgi.00311.2015

M3 - Article

VL - 310

SP - G155-G162

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0363-6119

IS - 3

ER -